Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
– ASP2138’s advancement into Phase 3 marks an important milestone in Astellas’ commitment to advancing research in CLDN18.2 with its…





